- Home
- FTHM vs LGVN Comparison
FTHM vs LGVN Comparison
Compare FTHM & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FTHM | LGVN |
|---|---|---|
| Founded | 2010 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.8M | 25.9M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | FTHM | LGVN |
|---|---|---|
| Price | $0.80 | $0.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $2.50 | ★ $3.00 |
| AVG Volume (30 Days) | 168.5K | ★ 200.0K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 32.71 | ★ 50.76 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $420,477,000.00 | $709,000.00 |
| Revenue This Year | $11.67 | N/A |
| Revenue Next Year | N/A | $10.81 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 25.45 | N/A |
| 52 Week Low | $0.40 | $0.48 |
| 52 Week High | $3.37 | $1.74 |
Technical Indicators
Market Signals| Indicator | FTHM | LGVN |
|---|---|---|
| Relative Strength Index (RSI) | 41.30 | 60.89 |
| Support Level | $0.70 | $0.72 |
| Resistance Level | $0.85 | $0.87 |
| Average True Range (ATR) | 0.05 | 0.04 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 0.00 | 80.56 |
Price Performance
Historical ComparisonAbout FTHM Fathom Holdings Inc.
Fathom Holdings Inc is a national, technology-driven, real estate services platform integrating residential brokerage, mortgage, title, and Software as a Service (SaaS) offerings to brokerages and agents by leveraging intelliAgent , proprietary cloud-based software. The Company's three operating and reportable segments: Real Estate Brokerage, Mortgage, and Title. The majority of revenue is from Real Estate Brokerage, which provides real estate brokerage services.
About LGVN Longeveron Inc.
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.